BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy. This very low voltage device, which does not penetrate the skin, further enhances the previously established tolerability of Inovio’s electroporation devices. Moreover, DNA vaccines delivered using this device produced strong antibody and T-cell immune responses and achieved protection from lethal challenge in multiple animal models including non-human primates. The lead author of the paper, “Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device,” was Dr. Niranjan Y. Sardesai, Senior Vice President, Research & Development. Other collaborators included Dr. David B. Weiner, Chair of Inovio’s Scientific Advisory Board and Professor, Department of Pathology & Laboratory Medicine, University of Pennsylvania.
